Saccade and cognitive function in chronic kava users

Neuropsychopharmacology

Volumn 28, Issue 2, 2003, Pages 389-396

  Cairney, Sheree ^a,b,c   Clough, Alan R ^c   Maruff, Paul ^a,b   Collie, Alex ^a   Currie, Bart J ^c   Currie, Jon ^a,d  

^a FLOREY INSTITUTE OF NEUROSCIENCE AND MENTAL HEALTH   (Australia)

^b LA TROBE UNIVERSITY   (Australia)

^c ROYAL DARWIN HOSPITAL   (Australia)

^d WESTMEAD HOSPITAL   (Australia)

Author keywords

Choreoathetosis; Chronic; Cognitive; Kava; Piper methysticum; Saccade

Indexed keywords

KAVA;

ADOLESCENT; ADULT; AGED; ANALYSIS OF VARIANCE; ARTICLE; COGNITION; COMPARATIVE STUDY; DRUG EFFECT; FEMALE; HUMAN; MALE; MIDDLE AGED; PHYSIOLOGY; SACCADIC EYE MOVEMENT;

ADOLESCENT; ADULT; AGED; ANALYSIS OF VARIANCE; COGNITION; FEMALE; HUMANS; KAVA; MALE; MIDDLE AGED; SACCADES;

EID: 0037311608     PISSN: 0893133X     EISSN: 1740634X     Source Type: Journal    
DOI: 10.1038/sj.npp.1300052     Document Type: Article

References (51)

1. American Psychiatric Association (1994).Diagnostic and Statistical Manual of Mental Disorders,4th edn. American Psychiatric Association: Washington, DC.
2. Baloh RW, Sills AW, Kumley WE, Honrubia V (1975). Quantitative measurement of saccade amplitude, duration and velocity.Neurology25: 1065-1070.
3. Becker (1989). Metrics. In: Wurtz RH, Goldberg ME (eds).Reviews of Oculomotor Research: The Neurobiology of Saccadic EyeMovements. Elsevier: Amsterdam.
4. Blumenthal M (2002). Kava safety questioned due to case reports of liver toxicity.http://www.herbalgram.org/browse.php/kavaupdate/.
5. Brunton R (1988). A harmless substance? Anthropological aspects of kava in the South Pacific. In: Prescott J, McCall G (eds).Kava:Use and Abuse in Australia and the South Pacific.(Sydney, National Drug and Alcohol Research Centre Monograph No 5).
6. Brust JCM (1993).Neurological Aspects of Substance Abuse.Butterworth-Heinemann: Boston.
7. Burns CB, d’Abbs P, Currie BJ (1995). Patterns of petrol sniffing and other drug use in young men from an Australian Aboriginalcommunity in Arnhem Land, Northern Territory.Drug AlcoholRev14: 159-169.
8. Cairney S, Maruff P, Clough AR (2002). The neurobehavioural effects of kava.Aust NZ J Psychiatry36: 657-662.
9. Cairney S, Maruff P, Vance A, Barnett R, Luk E, Currie J (2001). Contextual abnormalities of saccadic inhibition in childrenwith attention-deficit hyperactivity disorder.Exp Brain Res141:507-518.
10. Cawte J (1986). Parameters of kava used as a challenge to alcohol.Aust NZ J Psychiatry20: 70-76.
11. Clough AR, Bailie R, Burns CB, Guyula T, Wunungmurra R, Wanybarrnga SR (2002). Validity and utility of communityhealth workers’estimation of kava use.Aust NZ J Public Health26: 52-57.
12. Clough AR, Burns CB, Mununggurr N (2000). Kava in Arnhem Land: a review of consumption and its social correlates.DrugAlcohol Rev19: 319-328.
13. Clough AR, Cairney S, Maruff P, Burns CB, Currie BJ (2001). Possible toxicity and withdrawal seizures in Aboriginal kava drinkers inArnhem Land (Australia).South Pac J Psychol13: 26-33.
14. Clough AR, Guyula T, Yunupingu M (in press). Diversity of substance use in east Arnhem Land (Australia): patterns andrecent changes.Drug Alcohol Rev.
15. Collie A, Maruff P, Shafiq-Antonacci R, Smith M, Hallup M, Schofield PRet al(2001). Memory decline in healthy olderpeople: imfplications for identifying mild cognitive impairment.Neurology56: 1533-1538.
16. Currie BJ (2000). Infectious diseases of tropical Australia.Med Today1: 71-81.
17. Currie J, Joyce S, Maruff P, Ramsden B, McArthur-Jackson C, Malone V (1993). Selective impairment of express saccadegeneration in patients with schizophrenia.Exp Brain Res97:343-348.
18. Currie J, McArthur C, Ramsden B, Lynch J, Maruff P (1992). Highresolution eye movement recording in the early diagnosis of Huntington’s disease.Neuropsychiat Neuropsychol Behav Neurol5: 46-52.
19. Elliot R, Sahakian BJ, Matthews K, Bannerjea A, Rimmer J, Robbins TW (1997). Effects of methylphenidate on spatialworking memory and planning in healthy young adults.Psychopharmacology131: 196-206.
20. Escher M, Desmeules J, Giostra E, Mentha G (2001). Hepatitis associated with Kava, a herbal remedy for anxiety.Br Med J322:139.
21. Foo H, Lemon J (1997). Acute effects of kava, alone or in combination with alcohol, on subjective measures of impairmentand intoxication and on cognitive performance.Drug AlcoholRev16: 147-155.
22. Hall W, Solowij N (1997). Long-term cannabis use and mental health.Br J Psychiatry171: 107-108.
23. Hall W, Swift W (2000). The THC content of cannabis in Australia: evidence and implications.Aust NZ J Public Health24: 503-508.
24. Heinze HJ, Münte TF, Steitz J, Matzke M (1994). Pharmacological effects of oxazepam and kava-extract in a visual search paradigmassessed with event-related potentials.Pharmacopsychiatry27:224-230.
25. Hotson JR, Langston EB, Langston JW (1986). Saccade responses to dopamine in human MPTP-induced parkinsonism.AnnNeurol20: 456-463.
26. Lebot V, Merlin M, Lindstrom L (1997).Kava, the Pacific Elixir: The Definitive Guide to its Ethnobotany, History and Chemistry,2 edn. Healing Arts Press: Rochester, Vermont.
27. Leigh RJ, Zee DS (1999).The Neurology of Eye Movements,3rd edn. Oxford University Press: New York.
28. Maruff P, Burns CB, Tyler P, Currie BJ, Currie J (1998). Neurological and cognitive abnormalities associated withchronic petrol sniffing.Brain121: 1903-1917.
29. Maruff P, Tyler P, Burt T, Currie B, Burns C, Currie J (1996). Cognitive deficits in Machado-Joseph Disease.Ann Neurol40:421-427.
30. Mathews JD, Riley MD, Fejo L, Munoz E, Milns NR, Gardner IDet al(1988). Effects of the heavy usage of kava on physical health:summary of a pilot survey in an Aboriginal community.Med JAust148: 548-555.
31. Münte TF, Heinze HJ, Matzke M, Steitz J (1993). Effects of oxazepam and an extract of kava roots (piper methysticum) on event-related potentials in a word recognition task.Neuropsychobiology27: 46-53.
32. Owen AM, Roberts AC, Hodges JR, Summers BA, Polkey CE, Robbins TW (1993). Contrasting mechanisms of impairedattentional set-shifting in patients with frontal lobe damage orParkinson’s disease.Brain116: 1159-1175.
33. Owen AM, Sahakian BJ, Semple J, Polkey CE, Robbins TW (1995). Visuo-spatial short-term recognition memory and learning aftertemporal lobe excisions, frontal lobe excisions or amygdalohippocampectomy in man.Neuropsychologia33: 1-24.
34. Pantelis C, Barnes TRE, Nelson HE, Tanner S, Weatherly L, Owen AMet al(1997). Frontal-striatal cognitive deficits in patientswith chronic schizophrenia.Brain120: 1823-1843.
35. Prescott J, Jamieson D, Emdur N, Duffield P (1993). Acute effects of kava on measures of cognitive performance, physiologicalfunction and mood.Drug Alcohol Rev12: 49-58.
36. Purcell R, Maruff P, Kyrios M, Pantelis C (1998). Neuropsychological deficits in obsessive-compulsive disorder.Arch Gen Psychiatry55: 415-423.
37. Robbins TW, Semple J, Kumar R, Truman MI, Shorter J, Ferraro Aet al(1997). Effects of scopolamine on delayed-matching-to-sample and paired associates tests of visual memory andlearning in human subjects: comparison with diazepam andimplications for dementia.Psychopharmacology134: 95-106.
38. Russell PN, Bakker D, Singh N (1987). The effects of kava on alerting and speed of access of information from long-termmemory.Bull Psychon Soc25: 236-237.
39. Russmann S, Lauterburg BH, Helbling A (2001). Kava hepatotoxi-city.Ann Intern Med135: 68-69.
40. Sahakian BJ, Morris RG, Evenden JL, Heald A, Levy R, Philpot M (1988). A comparative study of visuospatial memory andlearning in Alzheimer-type dementia and Parkinson’s disease.Brain111: 695-718.
41. Sahakian BJ, Owen AM, Morant NJ, Eagger SA, Boddington S, Crayton Let al(1993). Further analysis of the cognitive effects oftetrahydroaminoacridine (THA) in Alzheimer’s disease: assessment of attentional and mnemonic function using CANTAB.Psychopharmacology110: 395-401.
42. Saletu B, Grünberger J, Linzmayer L, Anderer P (1989). EEG-brain mapping, psychometric and psychophysiological studies oncentral effects of kavain—a kava plant derivative.HumPsychopharm4: 169-190.
43. Schelosky L, Raffauf C, Jendroska K, Poewe W (1995). Kava and dopamine antagonism.J Neurol Neurosurg Psychiatry58:639-640.
44. Singh YN (1992). Kava: an overview.J Ethnopharmacol37: 13-45.
45. Smit AC, Van Gisbergen JA (1989). A short-latency transition in saccade dynamics during square-wave tracking and its significance for the differentiation of visually-guided and predictivesaccades.Exp Brain Res76: 64-74.
46. Solowij N, Stephens RS, Roffman RA, Babor T, Kadden R, Miller Met al(2002). Cognitive functioning of long-term heavy cannabisusers seeking treatment.J Am Med Assoc287: 1123-1131.
47. Spillane PK, Fisher DA, Currie BJ (1997). Neurological manifestations of kava intoxication.Med J Aust167: 172-173.
48. Tedeschi G, Bittencourt PR, Smith AT, Richens A (1983a). Specific oculomotor deficits after amylobarbitone.Psychopharmacology79: 187-189.
49. Tedeschi G, Bittencourt PR, Smith AT, Richens A (1983b). Effect of amphetamine on saccadic and smooth pursuit eye movements.Psychopharmacology79: 190-192.
50. Wang Z, Hoy W, McDonald S (2001). Body mass index in Aboriginal Australians in remote communities.Aust NZ J PublicHealth24: 570-575.
51. Wong AHC, Smith M, Boon HS (1998). Herbal remedies in psychiatric practice.Arch Gen Psychiatry55: 1033-1044.